The investigational therapy GB2064 reduced fibrosis in the bone marrow of patients with myelofibrosis, according to results of a phase 2A study released by the agent’s manufacturer.
Four of five patients treated with GB2064 (Galecto Inc.) — an inhibitor of lysyl oxidase-like 2 (LOXL2) — for at least 6 months experienced a grade 1 or greater reduction in collagen fibrosis of the bone marrow. All four of those patients showed stable hematologic parameters — such as white blood cell count, hemoglobin and thrombocytes — and stable spleen volume. None required